medigraphic.com
ISSN 2078-7170 (Digital)

2020, Número 4

<< Anterior Siguiente >>

CorSalud 2020; 12 (4)


Estructura y función ventriculares en la enfermedad de hígado graso no alcohólica

Cristiana MG, Donoiu I, Rogoveanu I

Idioma: Español
Referencias bibliográficas: 27
Paginas: 425-431
Archivo PDF: 590.77 Kb.


RESUMEN

La enfermedad del hígado graso no alcohólica se asocia al síndrome metabólico y a la enfermedad cardiovascular a través de múltiples vías patogénicas, que incluyen la resistencia a la insulina, la alteración del metabolismo lipídico, inflamación y disfunción endotelial. Estos mecanismos conducen a remodelación cardíaca, aterosclerosis y un aumento potencial de la morbilidad y la mortalidad cardiovasculares. En esta breve revisión se abordan las relaciones de la enfermedad del hígado graso no alcohólica con el síndrome metabólico y su impacto en las pruebas de imagen y en los marcadores bioquímicos de función ventricular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.

  2. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(8):948-63.

  3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.

  4. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109(18):2191-6.

  5. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110(19):3081-7.

  6. Di Bello V, Santini F, Di Cori A, Pucci A, Palagi C, Delle Donne MG, et al. Obesity cardiomyopathy: Is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr. 2006;19(8):1063-71.

  7. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res. 2003;11(4):518-24.

  8. Miyazato J, Horio T, Takishita S, Kawano Y. Fasting plasma glucose is an independent determinant of left ventricular diastolic dysfunction in nondiabetic patients with treated essential hypertension. Hypertens Res. 2002;25(3):403-9.

  9. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341-50.

  10. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, et al. Cardiac abnormalities as a new manifestation of non-alcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40(10):949-55.

  11. Fotbolcu H, Yakar T, Duman D, Karaahmet T, Tigen K, Cevik C, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J. 2010;17(5):457-63.

  12. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis. 2009;19(9):646-53.

  13. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015;62(3):773-83.

  14. Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Moller JE, Velazquez EJ, et al. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2013;61(23):2365-73.

  15. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2(5):356-64.

  16. Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS One [Internet]. 2015 [citado 14 Ene 2020];10(8):e0135329. Disponible en: https://doi.org/10.1371/journal.pone.0135329

  17. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012;35:389-95.

  18. Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol. 2016;221:275-9.

  19. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47(1):51-8.

  20. Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol. 2010;56(3):225-33.

  21. Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;291(2):E282-90.

  22. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52(22):1793-9.

  23. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170-5.

  24. Bekler A, Gazi E, Erbag G, Binnetoglu E, Barutcu A, Sen H, et al. Right ventricular function and its relationship with grade of hepatosteatosis in non-alcoholic fatty liver disease. Cardiovasc J Afr. 2015;26(3):109-13.

  25. Sunbul M, Kivrak T, Durmus E, Akin H, Aydin Y, Ergelen R, et al. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther. 2015;33(5):294-9.

  26. Mihailovici AR, Donoiu I, Gheonea DI, Mirea O, Târtea GC, Buse M, et al. NT-proBNP and echocardiographic parameters in liver cirrhosis - Correlations with disease severity. Med Princ Pract. 2019;28(5):432-41.

  27. Lazo M, Rubin J, Clark JM, Coresh J, Schneider AL, Ndumele C, et al. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015;62(4):841-7.




2020     |     www.medigraphic.com